Page 39 - GHES-3-3

Global Health Economics and
Sustainability
Semaglutide for treating T2D and obesity

Mentis, I. (2022). Impact of health indicators and socio-economic Ogundipe, O., Mazidi, M., Chin, K.L., Gor, D., McGovern, A.,
inequalities on Greek population’s health level in relation to Sahle, B.W., et al. (2021). Real-world adherence, persistence,
causes. Acta Scientific Medical Sciences, 6(4):3-12. and in-class switching during use of dipeptidyl peptidase-4
inhibitors: A systematic review and meta-analysis involving
Mentis, Ι. (2021). The market of generic drugs in Southern Europe
with the contribution of health technology assessment and 594,138 patients with type 2 diabetes. Acta Diabetologica,
competition. Arch Hellenic Medicine, 38:89-94. 58(1):39-46.
Mentis, Ι. (2022). The introduction of health technology https://doi.org/10.1007/s00592-020-01590-w
assessment (HTA) in Greece and comparison with the Pantanetti, P., Cangelosi, G., Alberti, S., Di Marco, S., Michetti, G.,
European experience. Archives of Hellenic Medicine/ Cerasoli, G., et al. (2024). Changes in body weight and
ArheiaEllenikesIatrikes, 39(3):313-321. composition, metabolic parameters, and quality of life in
Mentis, Ι. (2023). Correlation between the Greek gross domestic patients with type 2 diabetes treated with subcutaneous
product and health expenditure during the financial semaglutide in real-world clinical practice. Frontiers in
crisis, with emphasis on reimbursement of the cost of Endocrinology (Lausanne), 15:1394506.
diabetic health materials by the National Organization https://doi.org/10.3389/fendo.2024.1394506
for Healthcare Services Provision. Archives of Hellenic
Medicine, 40(2):260-269. Patel, T., Nageeta, F., Sohail, R., Butt, T.S., Ganesan, S.,
Madhurita, F., et al. (2023). Comparative efficacy and
Mishra, R., Raj, R., Elshimy, G., Zapata, I., Kannan, L., Majety, P., safety profile of once-weekly Semaglutide versus once-daily
et al. (2023). Adverse events related to tirzepatide. Journal of Sitagliptin as an add-on to metformin in patients with type 2
the Endocrine Society, 7(4):bvad016. diabetes: A systematic review and meta-analysis. Annals of
https://doi.org/10.1210/jendso/bvad016 Medicine, 55(2):2239830.
Morfonios, A., Kaitelidou, D., Baltopoulos, G., & https://doi.org/10.1080/07853890.2023.2239830
Myrianthefs, P. (2013). The international practice of health Pantanetti, P., Ronconi, V., Sguanci, M., Palomares, S. M., Mancin,
technology assessment. Archives of Hellenic Medicine/ S., Tartaglia, F. C. et al. (2024). Oral semaglutide in type 2
ArheiaEllenikesIatrikes, 30(1):19-34. diabetes: Clinical-metabolic outcomes and quality of life in
Morton, J.I., Marquina, C., Shaw, J.E., Liew, D., Polkinghorne, K.R., real-world practice. J Clin Med, 13(16):4752.
Ademi, Z., et al. (2023). Projecting the incidence and costs https://doi: 10.3390/jcm13164752
of major cardiovascular and kidney complications of type 2
diabetes with widespread SGLT2i and GLP-1 RA use: Rea, F., Savare, L., Valsassina, V., Ciardullo, S., Perseghin, G.,
A cost-effectiveness analysis. Diabetologia, 66(4):642-656. Corrao, G., et al. (2023). Adherence to antidiabetic drug
therapy and reduction of fatal events in elderly frail patients.
https://doi.org/10.1007/s00125-022-05832-0 Cardiovascular Diabetology, 22(1):53.
Mossialos, E., & Le Grand, J. (Eds.). (2019). Health Care and Cost https://doi.org/10.1186/s12933-023-01786-8
Containment in the European Union. London: Routledge.
Savarese, G., Sharma, A., Pang, C., Wood, R., & Soleymanlou, N.
Nauck, M.A., & Dietrich, J.W. (2022). Understanding the (2023). Patient preferences for newer oral therapies in type 2
restrictions in the prescription and use of potentially diabetes. International Journal of Cardiology, 371:526-532.
beneficial diabetes medications associated with low socio-
economic status. The Lancet Regional Health, 14:100318. https://doi.org/10.1016/j.ijcard.2022.09.009

https://doi.org/10.1016/j.lanepe.2022.100318 Seidu, S., Cos, X., Brunton, S., Harris, S.B., Jansson, S.P.O., Mata-
Cases, M., et al. (2022). 2022 update to the position statement
Ofori-Asenso, R., Ilomaki, J., Chin, K.L., Mazidi, M., Zomer, E., by Primary Care Diabetes Europe: A disease state approach
Bell, J.S., et al. (2019). Dynamics of switching, adherence, to the pharmacological management of type 2 diabetes in
and persistence of dipeptidyl peptidase-4 inhibitors use: primary care. Primary Care Diabetes, 16(2):223-244.
A nationwide cohort study. Diabetes Research and Clinical
Practice, 158:107909. https://doi.org/10.1016/j.pcd.2022.02.002
https://doi.org/10.1016/j.diabres.2019.107909 Smith, I., Hardy, E., Mitchell, S., & Batson, S. (2022). Semaglutide
2.4 Mg for the management of overweight and obesity:
Ofori-Asenso, R., Sahle, B.W., Chin, K.L., Mazidi, M., Systematic literature review and meta-analysis. Diabetes
Ademi, Z., De Bruin, M.L., et al. (2021). Poor adherence and
persistence to sodium glucose cotransporter 2 inhibitors in Metabolic Syndrome and Obesity, 15:3961-3987.
real-world settings: Evidence from a systematic review and https://doi.org/10.2147/DMSO.S392952
meta-analysis. Diabetes Metabolism Research and Reviews, Solar, O., & Irwin, A. (2010). A Conceptual Framework for Action
37(1):e3350. on the Social Determinants of Health. WHO Document
https://doi.org/10.1002/dmrr.3350 Production Services. Switzerland: WHO.

Volume 3 Issue 3 (2025) 31 https://doi.org/10.36922/ghes.8547